Literature DB >> 24419084

LEF1 and B9L shield β-catenin from inactivation by Axin, desensitizing colorectal cancer cells to tankyrase inhibitors.

Marc de la Roche1, Ashraf E K Ibrahim, Juliusz Mieszczanek, Mariann Bienz.   

Abstract

Hyperactive β-catenin drives colorectal cancer, yet inhibiting its activity remains a formidable challenge. Interest is mounting in tankyrase inhibitors (TNKSi), which destabilize β-catenin through stabilizing Axin. Here, we confirm that TNKSi inhibit Wnt-induced transcription, similarly to carnosate, which reduces the transcriptional activity of β-catenin by blocking its binding to BCL9, and attenuates intestinal tumors in Apc(Min) mice. By contrast, β-catenin's activity is unresponsive to TNKSi in colorectal cancer cells and in cells after prolonged Wnt stimulation. This TNKSi insensitivity is conferred by β-catenin's association with LEF1 and BCL9-2/B9L, which accumulate during Wnt stimulation, thereby providing a feed-forward loop that converts transient into chronic β-catenin signaling. This limits the therapeutic value of TNKSi in colorectal carcinomas, most of which express high LEF1 levels. Our study provides proof-of-concept that the successful inhibition of oncogenic β-catenin in colorectal cancer requires the targeting of its interaction with LEF1 and/or BCL9/B9L, as exemplified by carnosate. ©2014 AACR

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24419084      PMCID: PMC3947273          DOI: 10.1158/0008-5472.CAN-13-2682

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Thermodynamics of the high-affinity interaction of TCF4 with beta-catenin.

Authors:  S Knapp; M Zamai; D Volpi; V Nardese; N Avanzi; J Breton; S Plyte; M Flocco; M Marconi; A Isacchi; V R Caiolfa
Journal:  J Mol Biol       Date:  2001-03-09       Impact factor: 5.469

Review 2.  Drugging Wnt signalling in cancer.

Authors:  Paul Polakis
Journal:  EMBO J       Date:  2012-05-22       Impact factor: 11.598

3.  The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells.

Authors:  Marc van de Wetering; Elena Sancho; Cornelis Verweij; Wim de Lau; Irma Oving; Adam Hurlstone; Karin van der Horn; Eduard Batlle; Damien Coudreuse; Anna Pavlina Haramis; Menno Tjon-Pon-Fong; Petra Moerer; Maaike van den Born; Gwen Soete; Steven Pals; Martin Eilers; Rene Medema; Hans Clevers
Journal:  Cell       Date:  2002-10-18       Impact factor: 41.582

4.  Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions.

Authors:  Felix H Brembeck; Thomas Schwarz-Romond; Jeroen Bakkers; Sabine Wilhelm; Matthias Hammerschmidt; Walter Birchmeier
Journal:  Genes Dev       Date:  2004-09-01       Impact factor: 11.361

5.  Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements.

Authors:  Michael T Veeman; Diane C Slusarski; Ajamete Kaykas; Sarah Hallagan Louie; Randall T Moon
Journal:  Curr Biol       Date:  2003-04-15       Impact factor: 10.834

6.  Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.

Authors:  Shih-Min A Huang; Yuji M Mishina; Shanming Liu; Atwood Cheung; Frank Stegmeier; Gregory A Michaud; Olga Charlat; Elizabeth Wiellette; Yue Zhang; Stephanie Wiessner; Marc Hild; Xiaoying Shi; Christopher J Wilson; Craig Mickanin; Vic Myer; Aleem Fazal; Ronald Tomlinson; Fabrizio Serluca; Wenlin Shao; Hong Cheng; Michael Shultz; Christina Rau; Markus Schirle; Judith Schlegl; Sonja Ghidelli; Stephen Fawell; Chris Lu; Daniel Curtis; Marc W Kirschner; Christoph Lengauer; Peter M Finan; John A Tallarico; Tewis Bouwmeester; Jeffery A Porter; Andreas Bauer; Feng Cong
Journal:  Nature       Date:  2009-09-16       Impact factor: 49.962

7.  LEF-1 and TCF4 expression correlate inversely with survival in colorectal cancer.

Authors:  Lydia Kriegl; David Horst; Jana A Reiche; Jutta Engel; Thomas Kirchner; Andreas Jung
Journal:  J Transl Med       Date:  2010-11-22       Impact factor: 5.531

8.  Wnt signalling pathway parameters for mammalian cells.

Authors:  Chin Wee Tan; Bruce S Gardiner; Yumiko Hirokawa; Meredith J Layton; David W Smith; Antony W Burgess
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

9.  Activity of the beta-catenin phosphodestruction complex at cell-cell contacts is enhanced by cadherin-based adhesion.

Authors:  Meghan T Maher; Annette S Flozak; Adam M Stocker; Anjen Chenn; Cara J Gottardi
Journal:  J Cell Biol       Date:  2009-07-20       Impact factor: 10.539

10.  Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer.

Authors:  Baozhi Chen; Michael E Dodge; Wei Tang; Jianming Lu; Zhiqiang Ma; Chih-Wei Fan; Shuguang Wei; Wayne Hao; Jessica Kilgore; Noelle S Williams; Michael G Roth; James F Amatruda; Chuo Chen; Lawrence Lum
Journal:  Nat Chem Biol       Date:  2009-01-04       Impact factor: 15.040

View more
  39 in total

1.  A novel GSK3-regulated APC:Axin interaction regulates Wnt signaling by driving a catalytic cycle of efficient βcatenin destruction.

Authors:  Mira I Pronobis; Nasser M Rusan; Mark Peifer
Journal:  Elife       Date:  2015-09-22       Impact factor: 8.140

2.  Inhibition of Wnt/β-catenin pathway promotes regenerative repair of cutaneous and cartilage injury.

Authors:  Dikshya Bastakoty; Sarika Saraswati; Justin Cates; Ethan Lee; Lillian B Nanney; Pampee P Young
Journal:  FASEB J       Date:  2015-08-12       Impact factor: 5.191

3.  Tankyrase Sterile α Motif Domain Polymerization Is Required for Its Role in Wnt Signaling.

Authors:  Amanda A Riccio; Michael McCauley; Marie-France Langelier; John M Pascal
Journal:  Structure       Date:  2016-08-04       Impact factor: 5.006

4.  AXIN1 protects against testicular germ cell tumors via the PI3K/AKT/mTOR signaling pathway.

Authors:  Hailiang Xu; Yunyun Feng; Zhankui Jia; Jinjian Yang; Xueren Lu; Jun Li; Mingliang Xia; Chunru Wu; Yonggang Zhang; Jianhua Chen
Journal:  Oncol Lett       Date:  2017-05-19       Impact factor: 2.967

5.  A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors.

Authors:  Malini Menon; Richard Elliott; Leandra Bowers; Nicolae Balan; Rumana Rafiq; Sara Costa-Cabral; Felix Munkonge; Ines Trinidade; Roderick Porter; Andrew D Campbell; Emma R Johnson; Christina Esdar; Hans-Peter Buchstaller; Birgitta Leuthner; Felix Rohdich; Richard Schneider; Owen Sansom; Dirk Wienke; Alan Ashworth; Christopher J Lord
Journal:  Sci Rep       Date:  2019-01-17       Impact factor: 4.379

6.  Structure-Based Optimization of Small-Molecule Inhibitors for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.

Authors:  Min Zhang; Zhen Wang; Yongqiang Zhang; Wenxing Guo; Haitao Ji
Journal:  J Med Chem       Date:  2018-03-29       Impact factor: 7.446

7.  microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest.

Authors:  Zhenze Zhao; Xiuye Ma; Derek Sung; Monica Li; Adam Kosti; Gregory Lin; Yidong Chen; Alexander Pertsemlidis; Tzu-Hung Hsiao; Liqin Du
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

8.  The Poly(ADP-ribose) Polymerase Enzyme Tankyrase Antagonizes Activity of the β-Catenin Destruction Complex through ADP-ribosylation of Axin and APC2.

Authors:  Heather E Croy; Caitlyn N Fuller; Jemma Giannotti; Paige Robinson; Andrew V A Foley; Robert J Yamulla; Sean Cosgriff; Bradford D Greaves; Ryan A von Kleeck; Hyun Hyung An; Catherine M Powers; Julie K Tran; Aaron M Tocker; Kimberly D Jacob; Beckley K Davis; David M Roberts
Journal:  J Biol Chem       Date:  2016-04-11       Impact factor: 5.157

Review 9.  WNT signalling in prostate cancer.

Authors:  Virginia Murillo-Garzón; Robert Kypta
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

Review 10.  Scarless wound healing: finding the right cells and signals.

Authors:  Tripp Leavitt; Michael S Hu; Clement D Marshall; Leandra A Barnes; H Peter Lorenz; Michael T Longaker
Journal:  Cell Tissue Res       Date:  2016-06-02       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.